Assumpção Paula Baraúna, Canelas Erika Couto, Ramos Aline Cruz, Anaissi Ana, Acioli João Felipe, Ishak Geraldo, Santos Sidney, Demachki Samia, Assumpção Paulo
Laboratório Genética Humana e Médica, Universidade Federal do Pará, Belém-PA, Brasil.
Núcleo de Pesquisas em Oncologia, Hospital Universitário João de Barros Barreto, Belém-PA, Brasil.
Oncotarget. 2020 May 12;11(19):1729-1736. doi: 10.18632/oncotarget.27578.
adoptive immunotherapy is a promising cancer therapy. Immune cells are capable of recognizing and destroying cancer cells and represent a powerful strategy, however, this approach remains technically complicated, due to the need to select and isolate immune cells from these, present cancer antigens to those cells, expanding and reinjecting them. Lymph nodes recovered during gastric cancer surgery may represent an option for immunotherapy, since they harbor an enormous amount of immune cells, which have already been presented to cancer antigens. The advantage of selecting only cancer-negative lymph has not been determined yet. The status of immune checkpoints in the immune cells within the lymph nodes was analyzed in order to try to solve this problem.
Tissue microarrays were constructed and automated immunostaining for PD-1 and PD-L1 was performed on 143 lymph nodes from 70 patients with gastric adenocarcinoma.
In positive nodes, PD-L1 was only positivity in cancer cells (6%) and PD-1 was positive for B lymphocytes (60%), T lymphocytes (70%) and one case in cancer cells (2.5%). In negative nodes, most cases were positive for PD-1 in B (73.1%) and T (71.65%) lymphocytes.
Expression of PD-1 and PD-L1 in gastric cancer lymph nodes was demonstrated for the first time. PD-1 is expressed in positive and negative nodes, which could activate the PD-1 pathway. Lymphocytes from tumor-free lymph nodes were negative for PD-L1, and this might represent an advantage for selecting these lymph nodes as a potential source of immune cells for adoptive immunotherapy.
过继性免疫疗法是一种很有前景的癌症治疗方法。免疫细胞能够识别并摧毁癌细胞，这是一种强大的策略，然而，由于需要从这些细胞中选择和分离免疫细胞、向这些细胞呈递癌症抗原、扩增并重新注入它们，这种方法在技术上仍然很复杂。胃癌手术中回收的淋巴结可能是免疫疗法的一个选择，因为它们含有大量已经接触过癌症抗原的免疫细胞。仅选择癌阴性淋巴结的优势尚未确定。为了试图解决这个问题，对淋巴结内免疫细胞中的免疫检查点状态进行了分析。
构建组织微阵列，并对70例胃腺癌患者的143个淋巴结进行PD-1和PD-L1的自动免疫染色。
在阳性淋巴结中，PD-L1仅在癌细胞中呈阳性（6%），而PD-1在B淋巴细胞中呈阳性（60%）、T淋巴细胞中呈阳性（70%），在1例癌细胞中呈阳性（2.5%）。在阴性淋巴结中，大多数病例的B淋巴细胞（73.1%）和T淋巴细胞（71.65%）中的PD-1呈阳性。
首次证实了胃癌淋巴结中PD-1和PD-L1的表达。PD-1在阳性和阴性淋巴结中均有表达，这可能激活PD-1通路。无瘤淋巴结中的淋巴细胞PD-L1呈阴性，这可能是选择这些淋巴结作为过继性免疫疗法潜在免疫细胞来源的一个优势。
